BioSpace News Archive

Phio Pharmaceuticals Corp. today announced the appointment of Robert Bitterman as interim Executive Chairman of the Board of Directors.

NeuroBo Pharmaceuticals, Inc. (“NeuroBo”) (Nasdaq: NRBO) today announced that on September 27, 2022 , NeuroBo received formal notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC indicating that NeuroBo has evidenced full compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550.

NeuroSense Therapeutics Ltd. today announced it will participate in Cantor Fitzgerald’s Cantor Neurology and Psychiatry Conference scheduled to take place October 6-7, 2022 in San Francisco.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of its 2021 Environmental, Social and Governance (ESG) report detailing the company’s commitment to environmental sustainability, social equity and improved access to health care.

Kyowa Kirin, Inc. today announced the launch of new assets to help educate and empower adult patients to talk to their PD care team about the management of ‘off’ episodes, including treatment options like NOURIANZ® (istradefylline).

Cerebain Biotech Corp. (OTC: CBBT), (the “Company” or “Cerebain”) today announced that it has made a capital investment in Diabetes Reversal Group, LLC.

FSD Pharma Inc. today announced that on September 27, 2022 it received a written notification (the “ Notification Letter ”) from the Nasdaq Stock Market LLC (“ Nasdaq ”) that the Company is not in compliance with the minimum bid price requirement set forth in Nasdaq’s rules for continued listing on the Nasdaq Capital Market.

PDO MAX, Inc., a woman-owned aesthetics medical device company based in the United States, launches the first polydioxanone (PDO) topical serum skin booster called PDO AfterGlo™.

Beyeonics Vision, a medical device company, announced today that it has completed the registration process and received the CE Mark in Europe for its patented Beyeonics One™, a fully digital 3D surgical visualization platform.

Aditxt, Inc announces it has received confirmation from The Nasdaq Stock Market LLC Hearing Panel that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550, meets the stockholders’ equity requirement in Nasdaq Listing Rule 5550 and meets all other applicable criteria for continued listing.